Nazemroaya Behzad, Ghosouri Atefeh, Honarmand Azim, Hashemi Seyed Taghi
Anaesthesiology and Critical Care Research Centre, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Anaesthesiology and Critical Care, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Med Sci. 2021 Nov 29;26:106. doi: 10.4103/jrms.JRMS_951_19. eCollection 2021.
Electroconvulsive therapy (ECT) is nowadays used commonly as one the most effective treatment methods in psychiatric disorders. In patients undergoing ECT, succinylcholine is usually used. In addition, cisatracurium is occasionally used on a case report basis globally. In this study, we compared the hemodynamic changes and serum potassium levels in the use of succinylcholine and cisatracurium in ECT.
The current crossover clinical trial was performed on 45 patients who were candidates for ECT between 2017 and 2018. The patients were given succinylcholine or cisatracurium randomly on two separate occasions of ECT. The independent -test and Chi square Test were used to compare the data.
Comparison of mean systolic blood pressure ( = 0.14), diastolic blood pressure ( = 0.33), and mean arterial pressure ( = 0.23) did not show any significant difference between the two groups. The induced seizure duration ( = 0.002), return of spontaneous respiratory from seizure ending ( = 0.001), and apnea duration ( = 0.01) were significantly higher in the cisatracurium group compared to the succinylcholine group. However, the frequency of tachycardia in cisatracurium group was lower than the succinylcholine group ( < 0.001). In addition, the serum potassium level had a significant difference ( < 0.001) between the two groups.
Using cisatracurium can be an alternative to succinylcholine during ECT since it causes less elevation in serum potassium and creates a longer duration of induced seizure, more rapid re emergence of spontaneous breathing at the end of seizure ( = 0.001), and a lower prevalence of tachycardia compared to succinylcholine ( < 0.001).
如今,电休克疗法(ECT)是精神疾病最有效的治疗方法之一。接受ECT治疗的患者通常使用琥珀酰胆碱。此外,顺式阿曲库铵在全球范围内偶尔会基于病例报告使用。在本研究中,我们比较了ECT中使用琥珀酰胆碱和顺式阿曲库铵时的血流动力学变化和血清钾水平。
本交叉临床试验于2017年至2018年对45例ECT候选患者进行。患者在两次单独的ECT治疗中随机接受琥珀酰胆碱或顺式阿曲库铵。使用独立样本t检验和卡方检验比较数据。
两组间平均收缩压(P = 0.14)、舒张压(P = 0.33)和平均动脉压(P = 0.23)的比较未显示出任何显著差异。与琥珀酰胆碱组相比,顺式阿曲库铵组的诱发癫痫持续时间(P = 0.002)、癫痫结束后自主呼吸恢复时间(P = 0.001)和呼吸暂停持续时间(P = 0.01)显著更长。然而,顺式阿曲库铵组的心动过速频率低于琥珀酰胆碱组(P < 0.001)。此外,两组间血清钾水平存在显著差异(P < 0.001)。
在ECT期间使用顺式阿曲库铵可替代琥珀酰胆碱,因为与琥珀酰胆碱相比,它导致血清钾升高较少,诱发癫痫持续时间更长,癫痫结束时自主呼吸恢复更快(P = 0.001),心动过速发生率更低(P < 0.001)。